Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2020 September;66(3) > Minerva Gastroenterologica e Dietologica 2020 September;66(3):187-93

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   Free accessfree

Minerva Gastroenterologica e Dietologica 2020 September;66(3):187-93

DOI: 10.23736/S1121-421X.20.02673-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Pilot study on non-celiac gluten sensitivity: effects of Bifidobacterium longum ES1 co-administered with a gluten-free diet

Francesco DI PIERRO 1 , Francesca BERGOMAS 2, Paolo MARRACCINI 2, Maria R. INGENITO 2, Lorena FERRARI 2, Luisella VIGNA 2

1 Scientific Department, Velleja Research, Milan, Italy; 2 Obesity and Work Center, Occupational Medicine Unit, Department of Preventive Medicine, Maggiore Polyclinic Hospital, IRCCS Ca’ Granda Foundation, Milan, Italy



BACKGROUND: Bifidobacterium longum ES1 is a strain probiotic, colonizing the human gut and capable of a degradative action on gliadin. In an attempt to find new nutritional solutions aimed at improving the quality of life of patients with non-celiac gluten sensitivity (NCGS) we evaluated the effectiveness of this strain, in association with a gluten-free diet, comparing its efficacy versus diet therapy alone.
METHODS: The experimental design included a non-randomized, open-label, 1:1 intervention study in parallel groups. Enrolled patients with symptoms attributable to NCGS, and with negative diagnoses of both wheat allergy and celiac disease, were included in this three-month trial divided into four outpatient visits (baseline, T1, T2 and T3). Fifteen patients for each group completed the experimental protocol.
RESULTS: Our results showed that a combination of diet and probiotic determined a more significant reduction in the frequency and intensity of intestinal and extra-intestinal symptoms, and a clear improvement in stool consistency.
CONCLUSIONS: Although the study was carried out on a small number of patients, the results of our pilot trial suggest that a combined strategy of naturally gluten-free diet therapy with administration of the probiotic strain ES1 appears to offer a greater advantage than the dietary regime alone in improving the clinical symptomatic picture and in stabilizing the intestinal microbiota.


KEY WORDS: Celiac disease; Gliadin; Microbiota; Probiotics; Food hypersensitivity; Wheat hypersensitivity

inizio pagina